blog
Intermediate updates for 2Q activity
The Golden Week holidays in Japan have come to an end, and we are enjoying fulfilling days surrounded by fresh greenery. We would like to briefly report on our April performance and the forecast for the second quarter.
<Overview>
* In our Obstetrics and Gynecology division, R&D is progressing smoothly, and we anticipate the completion of multiple functional prototypes by the end of June.
* Our Consulting division continues to build strong trust with clients. All three projects from the previous period have been extended, and we have secured a fourth new project, resulting in steady revenue growth. We have also launched business model consulting services in English, which have received excellent feedback and requests for additional participants.
* In our new Cardiovascular division, we have completed applications for two Grants-in-Aid for Scientific Research (Kakenhi). We eagerly await the results, which are expected to be announced between June and July.
<Market Analysis>
* In May, the International Federation of Fertility Societies (IFFS) and The Japanese Society for Regenerative Medicine (JSRM) jointly held their conferences at the Tokyo International Forum. Various discussions on reproductive medicine took place internationally. We reaffirmed that our diagnostic technology under development is a unique, highly niche technology with significant market needs, scale, and social significance, despite its uniqueness.
<HR>
Since our founding, infuse Life Science has engaged with several experts in the medical device industry on a contractual basis. We are pleased to officially welcome Kikuo Iwasaka, Shinichi Matsuno, Hiromi Ohsone, and Masuko Saito to our team, bringing our total number of members to eight.
Please see our team member page for more details:
https://infuselifescience.com/staff
2025 Q1 Closed as a Steady Start of New Fiscal Year
The cherry blossoms are in full bloom in Akishima City, Tokyo, where the infuse Life Science headquarters laboratory is located. Riding the warm spring breeze, our company also smoothly concluded the first quarter and has entered a new fiscal year.
I would like to share some key highlights with you.
<Financials>
- Q1 sales reached 122% against our target. Our LS (Life Science) consulting division has reliably executed support for identifying global clinical needs—a crucial starting point for developing marketable products—and for creating business plans using tools such as the Business Model Canvas. We have received very high praise for these efforts.
- Despite significant initial investments for two overseas business trips and infrastructure development, our profit resulted in only a slight deficit.
- In Q2, we anticipate a substantial deficit due to partial payment of executive compensation and a large-scale research and development consignment fee. However, this is essentially a temporary outlay for grant-funded research projects.
- We are operating with a very low cash burn rate, and if we exclude the grant-funded portion (effectively setting it to zero), our runway extends to over 200 months.
<Research and Development>
- Our ob-gyn division has been selected for two Tokyo Metropolitan Government subsidies, and we have commenced research and development in earnest.
- Under the "Femtech Development Support and Promotion Project for Women's Empowerment," we will conduct foundational development (functional prototyping) to realize a program medical device for exploring the causes of infertility.
- Under the "Medical Device Industry Entry Promotion Subsidy Project," we will manufacture a prototype of a medical device for treating the causes of infertility identified through the aforementioned subsidy project.
- In Q1, in addition to securing funding for the full-scale prototype development to be carried out in Q2, contracts and preparations with key partners progressed smoothly.
<Market Analysis and Latest Research in Reproductive Medicine>
- Technological innovation in the field of reproductive medicine is globally advancing, particularly in the United States. However, research in Japan, unfortunately, cannot be described as leading globally due to challenges such as difficulty in securing research funding, a limited number of researchers, and a small market size after commercialization.
- On the other hand, AI-driven analysis is progressing rapidly. The research on AI-based IVF planning by Olawande et al. at Eastern London University is of great interest. (DB Olawande, et al. 2025 Jan. AI in IVF. Journal of Gynecology Obstetrics and Human Reproduction. Retrieved from
https://doi.org/10.1016/j.jogoh.2024.102903 - Despite this environment in Japan, remarkable research findings have been published by researchers at Yokohama National University and others. They discovered that in individuals with male infertility, ectopic expression of mitochondrial proteins within sperm is associated with poor sperm activity. This could be a factor in improving the accuracy of IVF. (Fujisawa, et al. 2024 Oct. Ectopic expression of the mitochondrial protein COXFA4L3 in human sperm acrosome and its potential application in the selection of male infertility treatments. Reproductive Medicine and Biology. Retrieved from
https://doi.org/10.1002/rmb2.12602
<Q2 Activities>
- In Q2, we will advance the prototype development of the two projects in our ob-gyn division. We aim to complete the prototype of the device for exploring the causes of infertility to a certain level by the end of June, and for the therapeutic medical device, we aim to finalize the specifications and commence design work.
- The LS Consulting division will continue to support clients in "global product planning for marketable products" and "business model strategy development for selling them." Additionally, we will challenge ourselves with a new service: "introducing overseas partners to expand businesses." Also, we are planning to partner with a NJ/USA-based consultant who is very active, knowledgeable, experienced expert of medical device business development and its strategy building.
- Furthermore, as a new initiative, we have begun research in the cardiovascular field. Through partnering with a leading KOL in Japan, we have embarked on basic research that will be the starting point for developing a world-first medical device. We have high expectations for this idea and technology to become a significant business in the future.
Thank you for your continued support of infuse Life Science.
Sincerely,
Dai Saito
CEO of infuse Life Science, Inc.
At UCSF with my greater boss, Prof. Alan Wu.
Confident business result for first fiscal year 2024
Happy New Year 2025 / 謹賀新年
Happy New Year!
We would like to express our sincere gratitude for your continued support and patronage in the past year.
As we embark on a new year, our team remains committed to driving innovative research and development to improve women's health and well-being. This year, we will be focusing our efforts on advancing R&D, with the aim of completing a pre-production mockup of two devices.
We look forward to another year of collaboration and growth. Thank you for your continued support.
新年あけましておめでとうございます。
旧年中は格別のご厚情を賜り、誠にありがとうございました。
本年も、社員一同、革新的な研究開発に邁進し、人々の健康と豊かな未来の実現に貢献してまいります。
皆様の一層のご支援を賜りますよう、お願い申し上げます。
元旦
Dai
half month of progress
2 weeks flew away so quickly
Hello friends of infuseLS!
We're excited to share some of the recent developments at infuse Life Science.
1. Tokyo SME Grant Application We're thrilled to announce that we've successfully re-submitted one of our applications for the Tokyo SME Grant after in-person official interview by the organization. This grant will significantly contribute to our ongoing R&D efforts for the therapeutic project, allowing us to push the boundaries of innovation.
2. Fukushima Study Group Meeting Last weekend, I had the privilege of attending a study group meeting in Fukushima. The event was incredibly informative and provided valuable insights into the latest industry trends and innovations. We're excited to apply these learnings to our own research and development projects as well as consultation service.
3. R&D Meeting at TAMA Headquarters Lab Our team of medical device experts and specialists convened at our TAMA headquarters lab for a productive R&D meeting. We made significant progress in aligning our product vision and reached a consensus on several key aspects of our development strategy. This will be definitely the world-first and world-only technology. Can’t wait for disclosing timing!
4. JDDW
Participating in JDDW in Kobe for me is actually not really the core activity but good to connect people from global medical device researchers. I met some good old friends there as well. AI in GI field has grown exponentially.
5. A Token of Friendship We were delighted to receive a beautiful flower arrangement fromy long-relationship old business friend in Australia, Nejim from JIMHANS. This thoughtful gesture reminds us of the global connections we've forged and the supportive community we're a part of.
And we always welcome flowers from you as we love woking with flowers in the lab😆💐
https://www.bunchesbaskets.jp/
https://www.worldflower.net/shop/index.php?site=w2
I visited Torinoichi in Asakusa with Aki and our daughter, Carla. Torinoichi is a market for to pray for good luck and business prosperity. This traditional event backed to Edo era. We got the smallest size of bench top Kumade ship as the very beginning of our journey. We start this size but will promise to grow larger and larger soon!
We're committed to delivering innovative medical devices that improve patient outcomes. Stay tuned for more updates on our progress and future milestones.
Thank you for your continued support.
Dai, CEO
infuse Life Science
